XML 42 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial assets and liabilities measured at fair value on a recurring basis
The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2014:
 
 
Fair Value Measurements at
 
December 31, 2014
 
Total
 
Using Quoted Prices
in Active Markets
for Identical Assets
(Level 1)
 
Using Significant
Other Unobservable
Inputs
(Level 2)
 
Using Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
36,474,066

 
$
36,474,066

 
$

 
$

Mutual funds
29,273,635

 

 
29,273,635

 

US corporate debt securities
23,802,339

 

 
23,802,339

 

Investment in affiliated entity
12,340,811

 
12,340,811

 

 

Common stock warrants
550,000

 

 

 
550,000

Total Assets
$
102,440,851

 
$
48,814,877

 
$
53,075,974

 
$
550,000

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
2,022,729

 
$

 
$

 
$
2,022,729

Total Liabilities
$
2,022,729

 
$

 
$

 
$
2,022,729


The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2013:
 
 
Fair Value Measurements at
 
December 31, 2013
 
Total
 
Using Quoted Prices
in Active Markets
for Identical Assets
(Level 1)
 
Using Significant
Other Unobservable
Inputs
(Level 2)
 
Using Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
26,852,560

 
$
26,852,560

 


 
$

Mutual funds
18,099,904

 

 
18,099,904

 

Municipal bonds
805,704

 

 
805,704

 

Investment in affiliated entity
9,664,587

 
9,664,587

 

 

Common stock warrants
717,500

 

 

 
717,500

Total Assets
$
56,140,255

 
$
36,517,147

 
$
18,905,608

 
$
717,500

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
19,540,583

 
$

 
$

 
$
19,540,583

Total Liabilities
$
19,540,583

 
$

 
$

 
$
19,540,583

Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair values of common stock warrants at December 31, 2014 and 2013 are presented below:
 
 
Year Ended December 31,
 
2014
 
2013
Risk-free interest rate
1.1%
 
0.1%-1.8%
Expected volatility
81%
 
90%-112%
Expected life in years
3.70
 
.50-4.70
Dividend yield
 
Change in fair value of the financial assets
The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the years ended December 31, 2014 and 2013:

 
Year Ended December 31,
 
2014
 
2013
Balance at beginning of year
$
717,500

 
$
267,200

(Decrease) Increase in fair value included in change in fair value of common stock warrants
(167,500
)
 
450,300

Balance at end of year
$
550,000

 
$
717,500



Changes in fair value of the financial liabilities
The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the years ended December 31, 2014 and 2013:
 
 
Year Ended December 31,
 
2014
 
2013
Balance at beginning of year
$
19,540,583

 
$
2,859,899

Record fair value of warrants issued in March 2013 financing

 
5,968,244

(Decrease) Increase in fair value included in change in fair value of common stock warrants
(515,643
)
 
46,082,969

Change in classification from liability to stockholders' equity due to warrant exercises
(17,002,211
)
 
(35,370,529
)
Balance at end of year
$
2,022,729

 
$
19,540,583

OncoSec  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair values of the OncoSec common stock warrants at December 31, 2014 and 2013 are presented below:

 
Year Ended December 31,
 
2014
 
2013
Risk-free interest rate
0.67%
 
0.78%
Expected volatility
90%
 
85%
Expected life in years
1.75-2.25
 
2.75-3.25
Dividend yield